NCT03207529
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: AR+, ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must also be PTEN+
Exclusions: Patient has central nervous system (CNS) tumor involvement or active leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03207529